Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies

Oncogene volume 30, pages 1497–1505 (2011)Cite this article

Subjects

Abstract

Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG et al. (2007). Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13: 170–181.

    Article  CAS  PubMed  Google Scholar 

  • Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J et al. (2001). A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91: 1543–1548.

    Article  CAS  PubMed  Google Scholar 

  • Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE . (2002). Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32: 123–132.

    Article  PubMed  Google Scholar 

  • Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C et al. (2008). Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26: 963–970.

    Article  PubMed  Google Scholar 

  • Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A et al. (2002). Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13: 614–621.

    Article  CAS  PubMed  Google Scholar 

  • Berković MC, Altabas V, Herman D, Hrabar D, Goldoni V, Vizner B et al. (2007). A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Coll Antropol 31: 531–534.

    PubMed  Google Scholar 

  • Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B et al. (2007). Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 11: 264–271.

    Article  PubMed  Google Scholar 

  • Bushnell Jr DL, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Custem E et al. (2010). 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28: 1652–1659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Calhoun K, Toth-Fejel S, Cheek J, Pommier R . (2003). Serum peptide profiles in patients with carcinoid tumors. Am J Surg 186: 23–31.

    Article  Google Scholar 

  • Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F et al. (2008). Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 23: 292–300.

    Article  CAS  PubMed  Google Scholar 

  • Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95: 1148–1154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W et al. (2003). Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689–2696.

    Article  CAS  PubMed  Google Scholar 

  • Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET et al. (2001). Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92: 1101–1107.

    Article  PubMed  Google Scholar 

  • Forrer F, Waldherr C, Maecke HR, Mueller-Brand J . (2006). Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26: 703–707.

    CAS  PubMed  Google Scholar 

  • Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander Jr HR et al. (2004). Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136: 1176–1182.

    Article  PubMed  Google Scholar 

  • Hodul PJ, Strosberg JR, Kvols LK . (2008). Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 15: 314–321.

    Article  PubMed  Google Scholar 

  • Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S . (2004). Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother Pharmacol 53: 337–340.

    Article  CAS  PubMed  Google Scholar 

  • Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D et al. (2008). Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31: 271–279.

    Article  PubMed  Google Scholar 

  • Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K et al. (2006). Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 17: 47–53.

    Article  PubMed  Google Scholar 

  • Kolby L, Persson G, Franzen S, Ahren B . (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90: 687–693.

    Article  CAS  PubMed  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY et al. (1993). Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–731.

    Article  CAS  PubMed  Google Scholar 

  • Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J et al. (2005). Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103: 2128–2131.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX et al. (2006a). Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24: 3555–3561.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC et al. (2009). O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15: 338–345.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA et al. (2004a). A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101: 934–939.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M et al. (2004b). A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 22: 353–359.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J et al. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403–3410.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al. (2006b). Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401–406.

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW et al. (2006c). A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51: 1033–1038.

    Article  CAS  PubMed  Google Scholar 

  • Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP et al. (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124–2130.

    Article  CAS  PubMed  Google Scholar 

  • Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G et al. (2008). Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 8: 1205–1213.

    Article  CAS  PubMed  Google Scholar 

  • Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD . (2005). Current status of gastrointestinal carcinoids. Gastroenterology 128: 1717–1751.

    Article  PubMed  Google Scholar 

  • Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS et al. (2006). Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13: 572–581.

    Article  PubMed  Google Scholar 

  • Pavel ME, Baum U, Hahn EG, Hensen J . (2005). Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35: 179–185.

    Article  CAS  PubMed  Google Scholar 

  • Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T . (2006). Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26: 8–13.

    Article  CAS  PubMed  Google Scholar 

  • Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK . (1995). Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36–42, discussion 42-3.

    Article  CAS  PubMed  Google Scholar 

  • Reidy DL, Tang LH, Saltz LB . (2009). Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol 6: 143–152.

    Article  CAS  PubMed  Google Scholar 

  • Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW et al. (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM et al. (2007). TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451: 757–762.

    Article  CAS  PubMed  Google Scholar 

  • Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656–4663.

    Article  CAS  PubMed  Google Scholar 

  • Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P et al. (2004). Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80: 244–251.

    Article  CAS  PubMed  Google Scholar 

  • Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J et al. (2004). Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10: 6111–6118.

    Article  CAS  PubMed  Google Scholar 

  • Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M et al. (2006). Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12: 3997–4003.

    Article  CAS  PubMed  Google Scholar 

  • Solcia E, Kloppel G, Sobin L . WHO International Histologic Classification of TUMORS (Springer-Verlag, Berlin, Germany, 2000).

    Google Scholar 

  • Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A et al. (2004). Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 22: 75–81.

    Article  CAS  PubMed  Google Scholar 

  • Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG . (2005). Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23: 4897–4904.

    Article  CAS  PubMed  Google Scholar 

  • Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD et al. (2005). Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241: 776–783, discussion 783-5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M et al. (2007). Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 11: 1680–1685.

    Article  PubMed  Google Scholar 

  • Varker KA, Campbell J, Shah MH . (2008). Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61: 661–668.

    Article  CAS  PubMed  Google Scholar 

  • Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M et al. (2009). Biochemical testing for neuroendocrine tumors. Pancreas 38: 876–889.

    Article  PubMed  Google Scholar 

  • Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K et al. (2007). Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13: 234–240.

    Article  CAS  PubMed  Google Scholar 

  • Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S et al. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26: 4311–4318.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC et al. (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26: 1316–1323.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Ohio State University, Columbus, OH, USA

    C Schmidt & M Bloomston

  2. Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

    M H Shah

Authors
  1. C Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Bloomston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M H Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M H Shah.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, C., Bloomston, M. & Shah, M. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene 30, 1497–1505 (2011). https://doi.org/10.1038/onc.2010.548

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.548

Keywords

This article is cited by

Search

Advanced search

Quick links